1887
  1. Home
  2. A-Z Publications
  3. Qatar Medical Journal
  4. Volume 2013, Issue 2
  5. Article
Volume 2013, Issue 2
  • ISSN: 0253-8253
  • EISSN: 2227-0426

Abstract

Vitiligo is an acquired pigmentry disorder of the skin and mucous membranes which manifests as white macules and patches due to selective loss of melanocytes. Etiological hypotheses of vitiligo include genetic, immunological, neurohormonal, cytotoxic, biochemical, oxidative stress and newer theories of melanocytorrhagy and decreased melanocytes survival. There are several types of vitiligo which are usually diagnosed clinically and by using a Wood's lamp; also vitiligo may be associated with autoimmune diseases, audiological and ophthalmological findings or it can be a part of polyendocrinopathy syndromes. Several interventions are available for the treatment for vitiligo to stop disease progression and/or to attain repigmentation or even depigmentation. In this article, we will present an overall view of current standing of vitiligo research work especially in the etiological factors most notably the genetic components, also, types and associations and various and newer treatment modalities.

© 2013 Allam, Riad, licensee Bloomsbury Qatar Foundation Journals.
Loading

Article metrics loading...

/content/journals/10.5339/qmj.2013.10
2014-05-01
2024-11-20
Loading full text...

Full text loading...

/deliver/fulltext/qmj/2013/2/qmj.2013.10.html?itemId=/content/journals/10.5339/qmj.2013.10&mimeType=html&fmt=ahah

References

  1. Picardo M. Taiieb A: Vitiligo. Heidelberg: Springer 2010.
     [Google Scholar]
  2. Birlea SA, Spritz RA. Norris DA: Vitiligo. In: Wolff K, ed. Fitzpatric's Dermatology in General Medicine. 8th ed. New York: McGraw-Hill in press.
     [Google Scholar]
  3. Alkhateeb A, Fain PR, Thody A, Bennett DC, Spritz RA. Epidemiology of vitiligo and associated autoimmune diseases in Caucasian probands and their relatives. Pigment Cell Res. 2003; 16:: 208–214.
     [Google Scholar]
  4. Kyriakis KP, Palamaras I, Tsele E, Michailides C, Terzoudi S. Case detection rates of vitiligo by gender and age. Int J Dermatol. 2009; 48::328–329.
     [Google Scholar]
  5. Alikhan A, Felsten LM, Daly M, Petronic-Rosic V. Vitiligo: A comprehensive overview Part 1. Introduction, epidemiology, quality of life, diagnosis, differential diagnosis, associations, histopathology, etiology, and work up. J Am Acad Dermatol. 2011; 65::473–491.
     [Google Scholar]
  6. Nordlund JJ, Ortonne J-P. Vitiligo Vulgaris. In: Nordlund JJBoissy REHearing VJKing RAOrtonne J-P, eds. The Pigmentry System. New York: Oxford University Press 1993;:513–551.
     [Google Scholar]
  7. Hann S-K, Nordlund J. Vitiligo. Oxford: Blackwell Science 2000.
     [Google Scholar]
  8. Spritz RA. The genetics of generalized vitiligo and associated autoimmune diseases. J Dermatol Science. 2006; 41::3–10.
     [Google Scholar]
  9. Linthorst Homan MW, Sprangers MA, de Korte J, Bos JD, van der Veen JP. Characteristics of patients with universal vitiligo and health related quality of life. Arch Dermatol. 2008; 144::1062–1064.
     [Google Scholar]
  10. Barona MI, Arrrunategui A, Falabella R, Alzate A. An epidemiologic case-control study in a population with vitiligo. J Am Acad Dermatol. 1995; 33::621–625.
     [Google Scholar]
  11. Halder RM, Taliaferro SJ. Vitiligo. In: Wolff K.Goldsmith LKatz SGilchrest BPaller ALefell D, eds. Fitzpatrick's dermatology in general medicine. New York: McGraw-Hill 2008:p.72.
     [Google Scholar]
  12. Spritz RA. Genetics. In: Picardo MTaieb A, eds. Vitiligo. Heidelberg: Springer-Verlag 2010:p.155.
     [Google Scholar]
  13. Alkhateeb A, Fain PR, Thody A, Bennett DC, Spritz RA. Epidemiology of vitiligo and associated autoimmune diseases in Caucasian probands and their families. Pigment Cell Res. 2003; 16::208–214.
     [Google Scholar]
  14. Hann SK, Lee HJ. Segmental vitiligo: clinical findings in 208 patients. J Am Acad Dermatol. 1996; 35::671–674.
     [Google Scholar]
  15. Gauthier Y, Cario Andre M, Taieb A. A critical appraisal of vitiligo etiologic theories. Is melanocyte loss a melanocytorrhagy? Pigment Cell Res. 2003; 16::322–332.
     [Google Scholar]
  16. Le Poole IC, Das PK, van den Wijngaard RM, Bos JD, Westerhof W. Review of the etiopathomechanism of vitiligo: a convergence theory. Exp Dermatol. 1993; 2::145–153.
     [Google Scholar]
  17. Grimes PE, Morris R, Avaniss-Aghajani E, Soriano T, Meraz A. Topical tacrolimus therapy in vitiligo: Therapeutic responses and skin messenger RNA expression of proinflammatory cytokines. J Am Acad Dermatol. 2004; 51::52–61.
     [Google Scholar]
  18. Rästep R, Kingo K, Karelson M, Reimann E, Raud K, Silm H, Vasar E, Kõks S. Gene expression study of IL10 family genes in vitiligo skin biopsies, peripheral blood mononuclear cells and sera. Br J Dermatol. 2008; 159::1275–1281.
     [Google Scholar]
  19. Reimann E, Kingo K, Karelson M, Reemann P, Loite U, Sulakatko H, Keermann M, Raud K, Abram K, Vasar E, Silm H, Kõks S. The mRNA expression profile of cytokines connected to the regulation of melanocyte functioning in vitiligo skin biopsy samples and peripheral blood mononuclear cells. Human Immunol. 2012; 73::393–398.
     [Google Scholar]
  20. Stimuli M, Ancans J, Thody AJ. Melanocyte function and its control by melanocortin peptides. J Histochem Cytochem. 2002; 50::125–133.
     [Google Scholar]
  21. Slominski A, Wortsman J, Mazurkeiwicz JE, Matsuoka L, Dietrich J, Lawrence K, Gorbani A, Paus R. Detection of proopiomelanocortin-derived antigens in normal and pathologic human skin. J Lab Clin Med. 1993; 122::658–666.
     [Google Scholar]
  22. Thody AJ, Ridley K, Penny RJ, Chalmers R, Fisher C, Shuster S. MSH peptides are present in mammalian skin. Peptides. 1983; 4::813–816.
     [Google Scholar]
  23. Pichler R, Sfetsos K, Badics B, Gutenbrunner S, Aubock J. Vitiligo patients present lower plasma levels of alpha melanotropin immunoreactivities. Neuropeptides. 2006; 40::177–183.
     [Google Scholar]
  24. Graham A, Westerhof W, Thody AJ. The expression of alpha-MSH by melanocytes is reduced in vitiligo. Ann NY Acad Sci. 1999; 885::470–473.
     [Google Scholar]
  25. Kingo K, Aunin E, Karelson M, Philips MA, Rästep R, Silm H, Vasar E, Soomets U, Kõks S. Gene expression analysis of melanocortin system in vitiligo. J Dermatol Sci. 2007; 48::113–122.
     [Google Scholar]
  26. Birlea SA, Gowan K, Fain PR, Spritz RA. Genome wide-association study of generalized vitiligo in an isolated European founder population identifies SMOC2, in close proximity to IDDM8. J Investig Dermatol. 2010; 130::798–803.
     [Google Scholar]
  27. Jin Y, Birlea SA, Fain PR, Gowan K, Riccardi SL, Holland PJ, Mailloux CM, Sufit AJD, Hutton SM, Amadi-Myers A, Bennett DC, Wallace MR, McCormack WT, Kemp EH, Gawkrodger DJ, Weetman AP, Picardo M, Leone G, Taieb A, Jouary T, Ezzedine K, van Geel N, Lambert J, Overbeck A, Spritz RA. Variant of TYR and autoimmunity susceptibility loci in generalized vitiligo. N Engl J Med. 2010; 362::1686–1697.
     [Google Scholar]
  28. Jin Y, Birlea SA, Fain PR, Mailloux CM, Riccardi SL, Gowan K, Holland PJ, Bennett DC, Wallace MR, McCormack WT, Kemp EH, Gawkrodger DJ, Weetman AP, Picardo M, Leone G, Taïeb A, Jouary T, Ezzedine K, van Geel N, Lambert J, Overbeck A, Spritz RA. Common variants of FOXP1 are associated with generalized vitiligo. Nat Genet. 2010; 42::576–578.
     [Google Scholar]
  29. Quan C, Ren YQ, Xiang LH, Sun LD, Xu AE, Gao XH, Chen HD, Pu XM, Wu RN, Liang CZ, Li JB, Gao TW, Zhang JZ, Wang XL, Wang J, Yang RY, Liang L, Yu JB, Zuo XB, Zhang SQ, Zhang SM, Chen G, Zheng XD, Li P, Zhu J, Li YW, Wei XD, Hong WS, Ye Y, Zhang Y, Wu WS, Cheng H, Dong PL, Hu DY, Li Y, Li M, Zhang X, Tang HY, Tang XF, Xu SX, He SM, Lv YM, Shen M, Jiang HQ, Wang Y, Li K, Kang XJ, Liu YQ, Sun L, Liu ZF, Xie SQ, Zhu CY, Xu Q, Gao JP, Hu WL, Ni C, Pan TM, Li Y, Yao S, He CF, Liu YS, Yu ZY, Yin XY, Zhang FY, Yang S, Zhou Y, Zhang XJ. Genome wide-association study for vitiligo identifies susceptibility loci at 6q27 and MHC. Nat Genet. 2010; 42::614–618.
     [Google Scholar]
  30. Liu J, Tang H, Zuo X, Liang B, Wang P, Sun L, Yang S, Zhang X. A single nucleotide polymorphism rs9468925 of MHC region is associated with clinical features of generalized vitiligo in Chinese Han population. J Eur Acad Dermatol Venereol. 2012; 26:9:1137–1141.
     [Google Scholar]
  31. Spritz LA. The genetics of generalized vitiligo: autoimmune pathways and inverse relation with malignant melanoma. Genome Med. 2010; 2::78–82.
     [Google Scholar]
  32. Birlea SA, Jin Y, Bennett DC, Herbstman DM, Wallace MR, McCormack WT, Kemp EH, Gawkrodger DJ, Weetman AP, Picardo M, Leone G, Taïeb A, Jouary T, Ezzedine K, van Geel N, Lambert J, Overbeck A, Fain PR, Spritz RA. Comprehensive association analysis of candidate genes for generalized vitiligo supports XBP1, FOXP3, AND TSLP. J Invest Dermatol. 2011; 131::371–381.
     [Google Scholar]
  33. Alkhateeb A, Qarqaz F. Genetic association of NALP1 with generalized vitiligo in Jordanian Arabs. Arch Dermatol Res. 2010; 302:8:631–634.
     [Google Scholar]
  34. Jin Y, Riccardi SL, Gowan K, Fain PR, Spritz RA. Fine-mapping of vitiligo susceptibility loci on chromosome 7 and 9 and interactions with NLRP1 (NALP1). J Invest Dermatol. 2010; 130::774–783.
     [Google Scholar]
  35. Ongenae K, Van Geel N, Naeyraert JM. Evidence of an autoimmune pathogenesis of vitiligo. Pigment Cell Res. 2003; 16::90–100.
     [Google Scholar]
  36. Sandoval-Cruz M, García-Carrasco M, Sánchez-Porras R, Mendoza-Pinto C, Jiménez-Hernández M, Munguía-Realpozo P, Ruiz-Argüelles A. Immunopathogenesis of vitiligo. Autoimmun Rev. 2011; 10::762–765.
     [Google Scholar]
  37. Passeron T, Ortonne JP. Pathophysiology and genetics of vitiligo. J Autoimmun. 2005; 25::63–68.
     [Google Scholar]
  38. Abu Tahir M, Pramod K, Ansari SH, Ali J. Current remedies for vitiligo. Autoimmun Rev. 2010; 9:7:516–520.
     [Google Scholar]
  39. Ali R, Ahsan MS, Azad MA, Ullah MA, Bari W, Islam SN, Yeasmin S, Hasnat A. Immunoglobulin levels in vitiligo patients. Pak J Pharm Sci. 2010; 23::96–102.
     [Google Scholar]
  40. Li YL, Yu CL, Yu HS. IgG anti-melanocyte antibodies purified from patients with active vitiligo induce HLA-DR and intercellular adhesion molecule 1expression and increased IL-8 release by melanocytes. J Invest Dermatol. 2000; 115::969–973.
     [Google Scholar]
  41. Kemp EH, Gavalas NG, Gawkrodger DJ, Weetman AP. Autoantibody responses to melanocytes in the depigmenting skin disease vitiligo. Autoimmun Rev. 2007; 3::138–142.
     [Google Scholar]
  42. Michelsen D. The Double Strike hypothesis of the vitiligo pathomechanism: New approaches to vitiligo and melanoma. Medical Hypotheses. 2010; 74::67–70.
     [Google Scholar]
  43. Klarquist J, Denmen CJ, Hernandez C, Wainwright DA, Strickland FM, Overbeck A, Mehrotra S, Nishimura MI, Le Poole IC. Reduced skin homing by functional Treg in vitiligo. Pigment Cell Melanoma Res. 2010; 23::276–286.
     [Google Scholar]
  44. van Geel NAC, Mollet IG, De Schepper S, Tjin EP, Vermaelen K, Clark RA, Kupper TS, Luiten RM, Lambert J. First histopathological and immunophenotypic analysis of early dynamic events in a patient with segmental vitiligo associated with halo nevi. Pigment Cell Melanoma Res. 2010; 23::375–384.
     [Google Scholar]
  45. Lili Y, Yi W, Ji Y, Yue S, Weimin S, Ming L. Global Activation of CD8+ Cytotoxic T Lymphocytes Correlates with an Impairment in Regulatory T Cells in Patients with Generalized Vitiligo. PloS ONE. 2012; 7::1–10.
     [Google Scholar]
  46. Zhou L, Li K, Shi YL, Hamzavi I, Gao TW, Henderson M, Huggins RH, Agbai O, Mahmoud B, Mi X, Lim HW, Mi QS. Systemic analyses of immunophenotypes of peripheral T cells in non-segmental vitiligo: implication of defective natural killer T cells. Pigment Cell Melanoma Res. 2012; 25::602–611.
     [Google Scholar]
  47. Hann SK, Chun W. Autocytotoxic hypothesis for the destruction of melanocytes as the cause of vitiligo. In: Hann SKNordlund J, eds. Vitiligo. Oxford: Blackwell Science Ltd 2000.
     [Google Scholar]
  48. Schallreuter KU, Wood JM, Berger J. Low catalase level in the epidermis in patients with vitiligo. J Invest Dermatol. 1991; 97::1081–1085.
     [Google Scholar]
  49. Schallreuter KU, Moore J, Wood JM, Beazley WD, Gaze DC, Tobin DJ, Marshall HS, Panske A, Panzig E, Hibberts NA. In vivo and in vitro evidence for hydrogen peroxide (H2O2) accumulation IN THE EPIDERMIS of patients with vitiligo and its successful removal by UVB-activated pseudocatalase. J Inest Dermatol Sym Proc. 1999; 4::91–96.
     [Google Scholar]
  50. Casp CB, She JX, McCormack WT. Genetic association of the catalase gene (CAT) with vitiligo susceptibility. Pigment Cell Res. 2002; 15::62–66.
     [Google Scholar]
  51. Glassman SJ. Vitiligo, reactive oxygen species and T-cells. Clinical Science. 2011; 120::99–120.
     [Google Scholar]
  52. Schallreuter KU, Wood JM, Pittelkow MR, Gutlich M, Lemke KR, Rodl W, Swanson NN, Hitzemann K, Ziegler I. Regulation of melanin biosynthesis in the human epidermis by tetrahydrobiopterin. Science. 1994; 263::1444–1446.
     [Google Scholar]
  53. Schallreuter KU, Buttner G, Pittelkow MR, Wood JM, Swanson NN, Korner C. Cytotoxicity of 6-biopterin to human melanocytes. Biochem Biophys Res Commun. 1994; 204::43–48.
     [Google Scholar]
  54. Le Poole IC, van den Wijngaard RM, Westerhof W, Das PK. Tenascin is overexpressed in vitiligo lesional skin and inhibits melanocyte adhesion. Br J Dermatol. 1997; 137::171–178.
     [Google Scholar]
  55. Kitamura R, Tsukamoto K, Harada K, Shimizu A, Shimada S, Kobayashi T, Imokawa G. Mechanisms underlying the dysfunction of melanocytes in vitiligo epidermis: rple od SCF/KIT interactions and the downstream effector MITF-M. J Pathol. 2004; 202::465–475.
     [Google Scholar]
  56. Lee AY, Kim NH, Choi WL, Youm YH. Less keratinocyte-derived factors related to more keratinocyte apoptosis in depigmented than normally pigmented suction-blistered epidermis may lead to may cause passive melanocyte death in vitiligo. J Invest Dermatol. 2005; 123::976–983.
     [Google Scholar]
  57. Ezzedine K, Lim HW, Suzuki T, Katayama I, Hamzavi I, Lan CC, Goh BK, Anbar T, Silva de Castro C, Lee AY, Parsad D, van Geel N, Le Poole IC, Oiso N, Benzekri L, Spritz R, Gauthier Y, Hann SK, Picardo M, Taieb A. Vitiligo Global Issue Consensus Conference Panelists. Revised classification/nomenclature of vitiligo and related issues: the Vitiligo Global Issues Consensus Conference. Pigment Cell Melanoma Res. 2012; 25::E1–E13.
     [Google Scholar]
  58. Mazereeuw-Hautier J, Bezio S, Mahe E, Bodemer C, Eschard C, Viseux V, Labreze C, Plantin P, Barbarot S, Vabres P, Martin L, Paul C, Lacour JP, Groupe de Recherche Clinique en Dermatologie Pédiatrique (GRCDP) . Segmental and nonsegmental childhood vitiligo have distinct clinical characteristics: A prospective observational study. J Am Acad Dermatol. 2010; 62::945–949.
     [Google Scholar]
  59. van Geel N, De Lille S, Vandenhaute S, Gauthier Y, Mollet I, Brochez L, Lambert J. Different phenotypes of segmental vitiligo based on a clinical observational study. J Eur Acad Dermatol Venereol. 2011; 25::673–678.
     [Google Scholar]
  60. Ingordo V, Gentile C, Lannazzone SS, Cusano F, Naldi L. Vitiligo and autoimmunity: an epidemiological study in a representative sample of young Italian males. Eur Acad Dermatol Venereol. 2011; 1::105–109.
     [Google Scholar]
  61. Akay BN, Bozkir M, Anadolu Y, Gullu S. Epidemiology of vitiligo, associated autoimmune diseases and audiological abnormalities: Ankara study of 80 patients in Turkey. J Eur Acad Dermatol Venereol. 2010; 24::1144–1150.
     [Google Scholar]
  62. Aslan S, Serarslan G, Teksoz E, Dagli S. Audiological and transient evoked otoacoustic emission findings in patients with vitiligo. Otolaryngol Head Neck Surg. 2010; 142::409–414.
     [Google Scholar]
  63. Bolognia JL, Orlow SJ. Melanocyte biology. In: Bolognia JLJorizzo JRapini PR, eds. Dermatology. 2nd ed. Spain: Mosby Elsevier 2008;:901–911.
     [Google Scholar]
  64. Schrott A, Spoendlin H. Pigment anomaly-associated inner ear deafness. Acta Otolaryngol. 1987; 7::17–32.
     [Google Scholar]
  65. Steel KP, Barkawy C. Another role for melanocytes: their importance for normal stria vascularis development in the mammalian inner ear. Development. 1989; 107::453–463.
     [Google Scholar]
  66. Shields CL, Ramasubramanian A, Kunz WB, Aggarwal E, Shields JA. Choroidal vitiligo masquerading as large choroidal nevus: a report of four cases. Ophthalmology. 2010; 117:1:109–113.
     [Google Scholar]
  67. Nordlund JJ, Taylor NT, Albert DM, Wagoner MD, Lerner AB. The prevalence of vitiligo and poliosis in patients with uveitis. J Am Acad Dermatol. 1981; 4::528–536.
     [Google Scholar]
  68. da Silva FT, Damico FM, Marin ML, Goldberg AC, Hirata CE, Takiuti PH, Olivalves E, Yamamoto JH. Revised diagnostic criteria for Vogt-Koyanagi-Harada disease: consideration on the different disease categories. Am J Ophthalmol. 2009; 147::339–345.
     [Google Scholar]
  69. Hamadah I, Binamer Y, Sanai FM, Abdo AA, Alajlan A. Interferon induced vitiligo in hepatitis C patients: a case series. Int J Dermatol. 2010; 49::829–833.
     [Google Scholar]
  70. Tinio P, Hadi A, Al-Ghaithi K, Al-Qari H, Rudikoff D. Segmental vitiligo and hair curling after interferon alpha and ribavirin treatment for hepatitis C. Skinmed. 2006; 5::50–51.
     [Google Scholar]
  71. Fattovich C, Giustina G, Favarato S, Ruol A. A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alpha interferon. J Hepatol. 1996; 24::38–47.
     [Google Scholar]
  72. Brenstien D, Reddy KR, Jeffers L, Scheiff E. Canities and vitiligo complicating interferon therapy for hepatitis C. Am J Gastenterol. 1995; 90::1176–1177.
     [Google Scholar]
  73. Tomasiewicz K, Modrzewska R, Semczuk G. Vitiligo associated with pegylated interferon and ribavirin treatment of patients with chronic hepatitis C: a case report. Adv Ther. 2006; 23::139–142.
     [Google Scholar]
  74. Primo J, Merino C, Gomez Belda AB. Vitiligo and alopecia in patients with chronic hepatitis C treated with alpha interferon associated or not with ribavirin. Gasterol Hepatol. 2000; 23::362–363.
     [Google Scholar]
  75. Simsek H, Savas C, Akkiz H, Telatar H. Interferon induced vitiligo in a patient with chronic hepatitis C infection. Dermatology. 1996; 193::65–66.
     [Google Scholar]
  76. Anbar TS, Abdel-Rahman AT, Ahmed HM. Vitiligo occurring at site of interferon α 2b injection in a patient with chronic viral hepatitis C: a case report. Clin Exp Dermatol. 2008; 33:4:503.
     [Google Scholar]
  77. Ayra V, Bansal M, Girard L, Arya S, Valluri A. Vitiligo at injection site of PEG-IFN α 2a in two patients with chronic hepatitis C: case report and literature review. Case Rep Dermatol. 2010; 2::156–164.
     [Google Scholar]
  78. Silverberg JI, Silverberg AI, Malka E, Silverberg NB. A pilot study assessing the role of 25 hydroxy vitamin D levels in patients with vitiligo vulgaris. J Am Acad Dermatol. 2010; 62:6:937–941.
     [Google Scholar]
  79. Silverberg NB. Update on childhood vitiligo. Curr Opion Pediatr. 2010; 22:4:445–452.
     [Google Scholar]
  80. Taieb A, Alomar A, Böhm M, Dell'anna ML, De Pase A, Eleftheriadou V, Ezzedine K, Gauthier Y, Gawkrodger DJ, Jouary T, Leone G, Moretti S, Nieuweboer-Krobotova L, Olsson MJ, Parsad D, Passeron T, Tanew A, van der Veen W, van Geel N, Whitton M, Wolkerstorfer A, Picardo M, Vitiligo European Task Force (VETF); European Academy of Dermatology and Venereology (EADV); Union Européenne des Médecins Spécialistes (UEMS) . Guidelines for the management of vitiligo: the European Dermatology Forum consensus. Br J Dermatol. 2012; 168::5–19.
     [Google Scholar]
  81. Gawkrodger DJ, Ormerod AL, Shaw L, Mauri-Sole I, Whitton ME, Watts MJ, Anstey AV, Ingham J, Young K, Therapy Guidelines and Audit Subcommittee, British Association of Dermatologists; Clinical Standards Department, Royal College of Physicians of London; Cochrane Skin Group; Vitiligo Society . Guideline for the diagnosis and management of vitiligo. Br J Dermatol. 2008; 159::1051–1076.
     [Google Scholar]
  82. Njoo MD, Spuls PI, Bos JD, Westerhof W, Bossuyt PM. Nonsurgical repigmentation therapies in vitiligo: meta-analysis of the literature. Arch Dermatol. 1998; 134::1532–1540.
     [Google Scholar]
  83. Westerhof W, Nieuwboer-Krobotova L, Mulder PGH, Glazenberg EJ. Left-right comparison study of the combination of fluticasone propionate and UV-A vs either fluticasone or UV-A alone for the long-term treatment of vitiligo. Arch Dermatol. 1999; 135::1061–1066.
     [Google Scholar]
  84. Kumari J. Vitiligo treated with topical clobetasol propionate. Arch Dermatol. 1984; 120::631–635.
     [Google Scholar]
  85. Schaffer JV, Bolognia JL. The treatment of hypopigmentation in children. Clin Dermatol. 2003; 21::296–310.
     [Google Scholar]
  86. Cockayne SE, Messenger AG, Gawkrodger DJ. Vitiligo treated with topical corticosteroids: children with head and neck involvement respond well. J Am Acad Dermatol. 2002; 46::964–965.
     [Google Scholar]
  87. Lepe V, Moncada B, Castanedo-Cazares JP, Torres-Alvares MB, Ortis CA, Torres-Rubalcava AB. A double-blind randomized trial of 0.1% tacrolimus vs clobetasol 0.05% for the treatment of childhood vitiligo. Arch Dermatol. 2003; 139::581–585.
     [Google Scholar]
  88. Coskun B, Saral Y, Tugurt D. Topical 0.05% clobetasol propionate vs 1% pimecrolimus oint in vitiligo. Eur J Dermatol. 2005; 15::88–91.
     [Google Scholar]
  89. Kwinter J, Pelletier J, Kambalia A, Pop E. High potency steroid use in children with vitiligo: a retrospective study. J Am Acad Dermatol. 2007; 56::236–241.
     [Google Scholar]
  90. Grimes PE, Soriano T, Dytoc MT. Topical tacrolimus for repigmentation of vitiligo. J Am Acad Dermatol. 2002; 47::789–791.
     [Google Scholar]
  91. Castro AP. Calcineurin inhibitors in the treatment of allergic dermatitis. J Pediatr. 2006; 82:5:s166–s172.
     [Google Scholar]
  92. Lan CCE, Wu CS, Chen GS, Yu HS. FK506 (tacrolimus) and endothelin combined treatment induce mobility of melanoblasts: new insight into follicular vitiligo repigmentation induced by topical tacrolimus in sun-exposed skin. Br J Dermatol. 2011; 164::490–496.
     [Google Scholar]
  93. Dawid M, Veensalu M, Grassberger M, Wolff K. Efficacy and safety of pimecrolimus cream 1% in adult patients with vitiligo: results of randomized, double-blind, vehicle-controlled study. J Dtsh Dermatol Ges. 2006; 4::942–946.
     [Google Scholar]
  94. Souze Leite RM, Craverio Leite AA. Two therapeutic challenges: periocular and genital vitiligo in children unsuccessfully treated with pimecrolimus cream. Int J Dermatol. 2007; 46::986–989.
     [Google Scholar]
  95. Ostavari N, Passeron T, Lacour JP, Ortonne JP. Lack of efficacy of tacrolimus in the treatment of vitiligo in the absence of UV-B exposure. Arch Dermatol. 2006; 142::252–253.
     [Google Scholar]
  96. Passeron T, Ostavari N, Zakaria W, Fontas E, Larroury JC, Lacour JP, Ortonne JP. Topical tacrolimus and 308-excimer laser: a synergistic combination for the treatment of vitiligo. Arch Dermatol. 2004; 140::1065–1069.
     [Google Scholar]
  97. Hartmann A, Brocker EB, Hamm H. Occlusive treatment enhances the efficacy of tacrolimus 0.1% oint in adult patients with vitiligo: results of placebo-controlled 12-months prospective study. Acta Dermatol Venereol. 2008; 88::474–479.
     [Google Scholar]
  98. Hartmann A, Brocker EB, Hamm H. repigmentation of pretibial vitiligo with calcineurin inhibitors under occlusion. J Deutschen Dermat Ges. 2008; 6::383–385.
     [Google Scholar]
  99. Stinco G, Piccirillo F, Forcione M, Valent F, Patrone P. An open randomized study to compare narrow band UVB, topical pimecrolimus and topical tacrolimus in the treatment of vitiligo. Eur J Dermatol. 2009; 19::588–593.
     [Google Scholar]
  100. Hearn RM, Kerr AC, Rahim KF, Ferguson J, Dawe RS. Incidence of skin cancers in 3867 patients treated with narrow-band ultraviolet B phototherapy. Br J Dermatol. 2008; 159::931–935.
     [Google Scholar]
  101. Bhatnagar A, Kanwar AJ, Parsad D. Comparison of systemic PUVA and NB-UVB in the treatment of vitiligo: an open prospective study. J Eur Acad Dermatol Venereol. 2007; 21::638–642.
     [Google Scholar]
  102. El Mofty M, Mostafa W, Esmat S, Youssef R, Azzam O, Hunter N, El Hanafi G, Fawzi M. Narrow band UVB 311 nm in the treatment of vitiligo: two right-left comparison studies. Photodermatol Photoimmunol Photomed. 2001; 22::6–11.
     [Google Scholar]
  103. Mofty ME, Zaher H, Esmat S, Yossef R, Shahin Z, Bassioni D, Enani GE. PUVA and PUVB in vitiligo-are they equally effective? Photodermatol Photoimmunol Photomed. 2001; 17::159–163.
     [Google Scholar]
  104. US Food and Drug Administration web site. Available from: www.fda.gov .
  105. Sassi F, Cazzaniga S, Tessari G, Chatenoud L, Reseghetti A, Marchesi L, Girolomoni G, Naldi L. Randomized controlled trial comparing the effectiveness of 308-nm excimer laser alone or in combination with topical hydrocortisone 17-butyrate cream in the treatment of vitiligo of the face and neck. Br J Dermatol. 2008; 159::1186–1191.
     [Google Scholar]
  106. Kawalek AZ, Spencer JM, Phelps RG. Combined excimer laser and topical tacrolimus for the treatment of vitiligo: a pilot study. Dermatol Surg. 2004; 30::130–135.
     [Google Scholar]
  107. Goldinger SM, Dummer R, Schmid P, Burg G, Siefert B, Lauchli S. Combination of 308-nm xenon excimer laser and topical calcipotriol in vitiligo. J Eur Acad Dermatol Venereol. 2007; 21::504–508.
     [Google Scholar]
  108. Lu-yan T, Wen-wen F, Lei-hong X, Yi J, Zhi-zhong Z. Topical tacalcitol and 308-nm monochromatic excimer light: a synergistic combination for the treatment of vitiligo. Photodermatol Photoimmunol Photomed. 2006; 22::310–314.
     [Google Scholar]
  109. Lotti T, Buggiani G, Troiano M, Assad GB, Delescluse J, De Giorgi V, Hercogova J. Targeted and combination treatments for vitiligo. Comparative evaluation of different current modalities in 458 subjects. Dermatol Ther. 2008; 21:suppl 1:s20–s26.
     [Google Scholar]
  110. Wu CS, Hu SC, Lan CC, Chen GS, Chuo WH, Yu HS. Low-energy helium-neon laser therapy induces repigmentation and improves the abnormalities of cutaneous microcirculation in segmental-type vitiligo lesions. Kaohsiung J Med Sci. 2008; 24::180–189.
     [Google Scholar]
  111. Lan CC, Wu CS, Chiou MH, Hsieh PC, Yu HS. Low-energy helium-neon laser induces locomotion of immature melanoblasts and promotes melanogenesis of the more differentiated melanoblasts: recapitulation of vitiligo repigmentation in vitro. J Invest Dermatol. 2006; 126::2119–2126.
     [Google Scholar]
  112. Yu HS, Wu CS, Yu CL, Kao YH, Chiou MH. Helium-neon laser irradiation stimulates migration and proliferation in melanocytes and induces repigmentation in segmental-type vitiligo. J Invest Dermatol. 2003; 120::56–64.
     [Google Scholar]
  113. Pasricha JS, Seetharam KA, Dashore A. Evaluation of five different regimes for the treatment of vitiligo. Indian J Dermatol Venereol Leprol. 1989; 55::18–21.
     [Google Scholar]
  114. Pasricha JS, Khaitan BK. Oral mini-pulse therapy with betametha- sone in vitiligo patients having extensive or fast-spreading disease. Int J Dermatol. 1993; 32::753–757.
     [Google Scholar]
  115. Radakovic-Fijan S, Furnsinn-Fridl AM, Honigsmann H, Tanew A. Oral dexamethasone pulse treatment for vitiligo. J Am Acad Dermatol. 2001; 44::814–817.
     [Google Scholar]
  116. Kim SM, Lee HS, Hann SK. The efficacy of low-dose oral corticosteroids in the treatment of vitiligo. Int J Dermatol. 1999; 38::546–550.
     [Google Scholar]
  117. Rath N, Kar HK, Sabhnani S. An open labeled, comparative clinical study on ef?cacy and tolerability of oral minipulse of steroid (OMP) alone, OMP with PUVA and broad/narrow band UVB phototherapy in progressive vitiligo. Indian J Dermatol Venereol Leprol. 2008; 74::357–360.
     [Google Scholar]
  118. Dell'Anna ML, Picardo M. A review and new hypothesis for non-immunological pathogenetic mechanisms in vitiligo. Pigment Cell Res. 2006; 19::406–411.
     [Google Scholar]
  119. Prasad D, Pandhi R, Juneja A. Effectiveness of oral ginkgo biloba in treating limited, slowly spreading vitiligo. Clin Exp Dermatol. 2003; 28::285–287.
     [Google Scholar]
  120. Dell'Anna ML, Mastrofrancesco A, Sala R, Venturini M, Ottaviani M, Vidolin AP, Leone G, Calzavara PG, Westerhof W, Picardo M. Antioxidant and narrow band-UVB in the treatment of vitiligo: a double-blind placebo-controlled trial. Clin Exp Dermatol. 2007; 32::631–636.
     [Google Scholar]
  121. Middelkamp-Hup MA, Bos JD, Rius-Diaz F, Gonzales S, Westerhof W. Treatment of vitiligo vulgaris with narrow-band UVB and oral polypodium leucotomos extract: a randomized double-blind placebo-controlled study. J Eur Acad Dermato Venereol. 2007; 21::942–950.
     [Google Scholar]
  122. Schallreuter KU, Wood JM, Lemke KR, Levenig C. Treatment of vitiligo with a topical application of pseudocatalase and calcium in combination with short-term UVB exposure: a case study on 33 patients. Dermatology. 1995; 190::223–229.
     [Google Scholar]
  123. Schallreuter KU, Moore J, Behrens-Willams S, Panske A, Harari M. Rapid initiation of repigmentation in vitiligo with dead sea climatotherapy in combination with pseudocatalase (PC-KUS). Int J Dermatol. 2002; 41::482–487.
     [Google Scholar]
  124. Sanclemente G, Garcia JJ, Zuleta JJ, Diehl C, Correa C, Falabella R. A double-blind, randomized trial of 0.05% betamethasone vs topical catalase/dismutase superoxide in vitiligo. J Eur Acad Dermato Venereol. 2008; 22::1359–1364.
     [Google Scholar]
  125. Yuskel EP, Aydin F, Senturk N, Canturk T, Turanli AY. Comparison of the efficacy of narrow band ultraviolet B plus topical catalase-superoxide dismutase treatment in vitiligo patients. Eur J Dermatol. 2009; 19::341–344.
     [Google Scholar]
  126. Patel DC, Evans AV, Hawk JL. Topical pseudocatalase mousse and narrowband UVB phototherapy is not effective for vitiligo: an open, single-center study. Clin Exp Dermatol. 2002; 27::641–644.
     [Google Scholar]
  127. Kim CY, Yoon TJ, Kim TH. Epidermal grafting after chemical ablation in the treatment of vitiligo. Dermatol Sur. 2001; 27::855–856.
     [Google Scholar]
  128. Gupta S, Shroff S, Gupta S. Modified technique of suction blistering for epidermal grafting in vitiligo. Int J Dermatol. 1999; 38:306:9.
     [Google Scholar]
  129. Acikel C, Ulkur E, Celikoz B. Carbon dioxide laser resurfacing and thin skin graft in the treatment of “stable and recalcitrant” vitiligo. Plast Reconstr Surg. 2003; 111::1291–1298.
     [Google Scholar]
  130. Agrawal K, Agrawal A. Vitiligo: repigmentation with dermabrasion and thin split-thickness skin graft. Dermatol Sur. 1995; 21::295–300.
     [Google Scholar]
  131. Ozdemir M, Cetinkale O, Wolf R, Kotoğyan A, Mat C, Tüzün B, Tüzün Y. Comparison of two surigal approaches for treating vitiligo: a preliminary study. Int J Dermatol. 2002; 41::135–138.
     [Google Scholar]
  132. Lim JT. Repigmentation of vitiligo with autologous blister-induced epidermal graft. Ann Acad Med Singapore. 1992; 28::824–828.
     [Google Scholar]
  133. Awad SS, Abdel-Raof H, Hosam El-Din W, El-Domiaty M. Epithelial grafting for vitiligo requires ultraviolet A phototherapy to increase success rate. J Cosm Dermatol. 2007; 6::119–124.
     [Google Scholar]
  134. Malakar S, Dhar S. Treatment of stable and recalcitrant vitiligo by autologous miniature punch grafting: a prospective study of 1,000 patients. Dermatology. 1999; 198::133–139.
     [Google Scholar]
  135. Lahiri K, Malakar S, Sarma N, Banerjee U. Repigmentation of vitiligo with punch grafting and narrow-band UV-B (311 nm)—a prospective study. Int J Dermatol. 2006; 45::649–655.
     [Google Scholar]
  136. Pandya V, Parmar KS, Shah BJ, Bilimoria FE. A study of autologous melanocyte transfer in treatment of stable vitiligo. Indian J Dermatol Venereol Leprol. 2005; 71::393–397.
     [Google Scholar]
  137. van Geel N, Ongenae K, De Mil M, Haeghen YV, Vervaet C, Naeyaert JM. Double-blind placebo-controlled study of autologous transplanted epidermal cell suspensions for repig- menting vitiligo. Arch Dermatol. 2004; 140::1203–1208.
     [Google Scholar]
  138. Mulekar SV. Long-term follow-up study of 142 patients with vitiligo vulgaris treated by autologous, non-cultured melanocyte-keratinocyte cell transplantation. Int J Dermatol. 2005; 44::841–845.
     [Google Scholar]
  139. Khandpur S, Sharma VK, Manchanda Y. Comparison of minipunch grafting versus split-skin grafting in chronic stable vitiligo. Dermatol Surg. 2005; 31::436–441.
     [Google Scholar]
  140. Barman KD, Khaitan BK, Verma KK. A comparative study of punch grafting followed by topical corticosteroid versus punch grafting followed by PUVA therapy in stable vitiligo. Dermatol Surg. 2004; 30::49–53.
     [Google Scholar]
  141. Lahiri K, Malakar S, Sarma N, Banerjee U. Repigmentation of vitiligo with punch grafting and narrow-band UV-B (311 nm)—a prospective study. Int J Dermatol. 2006; 45::649–655.
     [Google Scholar]
  142. Tanioka M, Yamamoto Y, Kato M, Miyachi Y. Camou?age for patients with vitiligo vulgaris improved their quality of life. J Cos- met Dermatol. 2010; 9::72–75.
     [Google Scholar]
  143. DePase A. ‘La Voce dei Pazienti’. Evidence Based Dermatology. Milan: Masson Publisher 2003.
     [Google Scholar]
  144. Ongenae K, Dierckxsens L, Brochez L, van Geel N, Naeyaert JM. Quality of life and stig- matization pro?le in a cohort of vitiligo patients and effect of the use of camou?age. Dermatology. 2005; 210::279–285.
     [Google Scholar]
  145. Savin J. The hidden face of dermatology. Clin Exp Dermatol. 1993; 18::393–395.
     [Google Scholar]
  146. De Cuyper C. Permanent makeup: indications and complications. Clin Dermatol. 2008; 26::30–34.
     [Google Scholar]
  147. Mosher DB, Parrish JA, Fitzpatrick TB. Monobenzylether of hydroquinone. A retrospective study of treatment of 18 vitiligo patients and a review of the literature. Br J Dermatol. 1977; 97::669–679.
     [Google Scholar]
  148. Njoo MD, Vodegel RM, Westerhof W. Depigmentation therapy in vitiligo universalis with topical 4-methoxyphenol and the Q- switched ruby laser. J Am Acad Dermatol. 2000; 42::760–769.
     [Google Scholar]
  149. Rao J, Fitzpatrick RE. Use of the Q-switched 755-nm alexandrite laser to treat recalcitrant pigment after depigmentation therapy for vitiligo. Dermatol Surg. 2004; 30::1043–1045.
     [Google Scholar]
  150. Linthorst Homan MW, Spuls PI, De Korte J, Bos JD, Sprangers MA, van der Veen JP. The burden of vitiligo: patient characteristics associated with quality of life. J Am Acad Dermatol. 2009; 61::411–420.
     [Google Scholar]
  151. Thompson AR, Clarke SA, Newell RJ, Gawkrodger DJ, Appearance Research Collaboration . Vitiligo linked to stigmatization in British South Asian women: a qualitative study of the experiences of living with vitiligo. Br J Dermatol. 2010; 163::481–486.
     [Google Scholar]
  152. Kostoupolou P, Taieb A. Psychological interventions. In: Picardo MTaieb A, eds. Vitiligo. Berlin: Springer 2009;:433–435.
     [Google Scholar]
  153. Kostopolou P, Juoary T, Quintard B, Ezzedine K, Marques S, Boutchnei S, Taieb A. Objective vs. subjective factors in the psychological impact of vitiligo: the experience from a French referral center. Br J Dermatol. 2009; 161::128–133.
     [Google Scholar]
  154. Talsania N, Lamb B, Bewley A. Vitiligo is more than skin deep: a survey of members of the Vitiligo Society. Clin Exp Dermatol. 2009; 35::736–739.
     [Google Scholar]
  155. Birol A, Kisa U, Kurtipek GS, Kara F, Kocak M, Erkek E, Caglayan O. Increased tumor necrosis factor alpha (TNF-alpha) and interleukin 1 alpha (IL1-alpha) levels in the lesional skin of patients with nonsegmental vitiligo. Int J Dermatol. 2006; 45::992–994.
     [Google Scholar]
  156. Simon JA, Burgos-Vargas R. Vitiligo improvement in a patient with ankylosing spondylitis treated with infliximab. Dermatology. 2008; 216::234–235.
     [Google Scholar]
  157. Wakkee M, Assen YJ, Thio HB, Neumann HA. Repigmentation of vitiligo during eflizumab. J Am Acad Dermatol. 2008; 59:2 Suppl 1:S57–S58.
     [Google Scholar]
  158. Al-Mutairi N, Al-Doukhi A. Familial and colocalized psoriasis and vitiligo responding to alefacept. J Cutan Med Surg. 2009; 13::172–175.
     [Google Scholar]
  159. Radmanesh M, Saedi K. The Efficacy of combined PUVA and low-dose azathioprine for early and enhanced repigmentation in vitiligo patients. J Dermatol Treat. 2006; 17::151–153.
     [Google Scholar]
  160. Dogra S, Kumar B. Repigmentation in vitiligo universalis: role of melanocyte density, disease duration, and melanocytic reservoir. Dermatol Online J. 2005; 11:3:30.
     [Google Scholar]
  161. Pardue SL, Fite KV, Bengston L, Lamont SJ, Boyle ML 3rd, Smyth JR Jr. Enhanced integumental and ocular amelanosis following the termination of cyclosporine administration. J Invest Dermatol. 1987; 88::758–761.
     [Google Scholar]
  162. Mahmoud CL, Hexel IH. Update on new and emerging options for the treatment of vitiligo. Skin Ther Letter. 2008; 13:2:1–6.
     [Google Scholar]
  163. Sethi RR, Mahajan A. evaluation of the therapeutic efficacy of dermabrasion, dermabrasion combined with topical 5% 5-fluorouracil cream, and dermabrasion combined with topical Placentrex® gel in localized stable vitiligo. Int J Dermatol. 2007; 46:8:875–879.
     [Google Scholar]
  164. Whitton J, Pinart U, Batchelor J, Lushey C, Leonardi-Bee J, González U. for vitiligo. Cochrane Database Syst Rev. 2010; 20::1–142.
     [Google Scholar]
/content/journals/10.5339/qmj.2013.10
Loading
Concise review of recent studies in vitiligo
Qatar Medical Journal 2013, 10 (2014); https://doi.org/10.5339/qmj.2013.10
/content/journals/10.5339/qmj.2013.10
/content/journals/10.5339/qmj.2013.10
Loading

Data & Media loading...

  • Article Type: Review Article

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error